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Abstract
Emergency department (ED) settings have gained interest as venues for illegal drug misuse prevention and in-
tervention, with researchers and practitioners attempting to capitalize on the intersection of need and oppor-
tunity within these settings. This study of 686 adult patients visiting two EDs for various reasons who
admitted drug use compared daily cannabis-only users, nondaily cannabis-only users, and other drug users
on sociodemographic and drug-related severity outcomes. The three drug use groups did not differ on most
sociodemographic factors or medical problem severity scores. Forty-five percent of the sample was identified
as having a drug use problem. ED patients who used drugs other than cannabis were at particular risk for
high drug use severity indicators and concomitant problems such as psychiatric problems and alcohol use se-
verity. However, 19–29% of cannabis-only users were identified as having problematic drug use. Furthermore,
daily cannabis-only users fared less well than nondaily cannabis users with regard to drug use severity indicators
and self-efficacy for avoiding drug use. Results may assist emergency medicine providers and medical social
workers in matching patients to appropriate intervention. For example, users of drugs other than cannabis
(and perhaps heavy, daily cannabis-only users) may need referral to specialty services for further assessment.
Enhancement of motivation and self-efficacy beliefs could be an important target of prevention and treatment
for cannabis-only users screened in the ED.
Key words: addiction; behavior; drug abuse
Introduction
In the United States, the annual cost of drug abuse to
society related to lost productivity, crime, and health-
care is estimated to be $193 billion.1 Such use places
a significant burden on the healthcare system partly be-
cause drug users (including cannabis users) are more
likely than nondrug users to use the emergency depart-
ment (ED) as a primary source of medical care.2–5 ED
settings have gained interest as venues for drug abuse
prevention and intervention, with researchers and
practitioners attempting to capitalize on the intersec-
tion of need and opportunity within these settings.5
Cannabis use in the United States has steadily in-
creased over the past decade, whereas use of many
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other substances has declined.6 Those who use canna-
bis exclusively are typically in better health overall than
users of other drugs, although cannabis use can be as-
sociated with both acute and chronic psychosocial,
mental, and physical health consequences, including
cancer and long-term respiratory and cardiovascular
problems.7–10
With the passage of less punitive measures or out-
right legalization of cannabis use for medical and/or
recreational use in 23 states, as well as mounting evi-
dence of dose-dependent psychocognitive health effects
of cannabis,11,12 more information is needed about
users of cannabis only and how they compare with
other drug users who present to the ED. Such efforts
may shed light on differences in drug use patterns
and associated health effects, and provide important
information for future intervention efforts. This study
examined the sociodemographic characteristics, drug
use severity, and problems related to drug use among
ED patients who were daily versus nondaily cannabis-
only users, as well as those who reported noncannabis
drug use.
Materials and Methods
Procedures
Participants were 686 consecutively enrolled adult pa-
tients visiting the EDs and trauma units of two large
urban safety net hospitals in Southern California who
reported to trained paraprofessional health interview-
ers that they had used illicit drugs, or legal drugs in a
nonprescribed manner, during the past 30 days (addi-
tional details have been published elsewhere).13,14 Over
a 1-year period, interviewers working during peak
hours attempted to approach all capable adult patients,
regardless of the reason for the patient’s visit. Patients
under the age of 18, those with severely altered mental
status, those physically incapable of participating due
to severe illness or injury, and those unable to speak
English or Spanish were excluded from participation.
After providing consent, as approved by our university
and hospital IRBs, these patients were interviewed fur-
ther to collect sociodemographic information, addi-
tional drug use data, and measures of problem areas
related to drug use. Refusals to be screened by trained
interviewers were rare.14
Measures
Sociodemographic variables included participants’ age;
gender; race/ethnicity (Hispanic/Latino, white non-
Latino, African American, and other); marital status
(i.e., single, which included never married, divorced,
separated, or widowed, vs. married/living as married);
years of education; annual household income (mea-
sured by six categories ranging from less than $9999
to $50,000 or more); and whether or not the participant
had been employed in the past 30 days.
Participants completed the ASI-Lite, a condensed
version of the Addiction Severity Index.15,16 The ASI-
Lite gathers quantitative information (i.e., number of
days in the past 30 days) about the participant’s recent
use of several types of drugs (i.e., heroin, illicit metha-
done, other opiates/analgesics, barbiturates, sedatives/
hypnotics/tranquilizers, cocaine, amphetamines, can-
nabis/marijuana, hallucinogens, and ‘‘other drugs’’).
Fifty-seven percent of participants (n=394) were cannabis-
only users. Three drug use groups were created: (a)
cannabis-only users who reported using cannabis less
than every day during the past 30 days (n = 253), (b)
cannabis-only users who reported using cannabis
every day during the past 30 days (n = 141), and (c)
other drug users (n= 292) who reported using other
illegal or nonprescribed drugs either alone or in combi-
nation with cannabis. The ASI-Lite also collects infor-
mation about the number of days in the past 30 days
that one used alcohol, although alcohol did not fac-
tor into creation of the three drug use groups. The
ASI-Lite yields mathematically derived composite
severity scores of problem areas in the participant’s
life commonly affected by substance use, including a
drug use severity score, a medical problem score, a
psychiatric problem score, and an alcohol problem
score.15,16 ASI-Lite composite scores range from 0 to
1, with higher scores indicating greater severity of
the problem.
Participants also completed the 10-item drug abuse
screening test (DAST).17,18 Problematic drug use
(yes/no) was computed based on a DAST score greater
than or equal to 3, a cut-point that has demonstrated
accuracy in classifying patients according to Diagnos-
tic and Statistical Manual of Mental Disorders (DSM)
classification. Self-efficacy for avoiding drug use was
measured using a four-item scale assessing confi-
dence in avoiding drug use in various situations, with
scores ranging from 1 (low confidence) to 5 (high
confidence).19
Analyses
After ruling out problems related to multicollinearity
among the correlates, ANOVA and chi-square bivari-
ate analyses were conducted to assess differences
Woodruff, et al.; Cannabis and Cannabinoid Research 2016, 1.1
http://online.liebertpub.com/doi/10.1089/can.2016.0012
150
among the three drug use groups’ sociodemographic
characteristics, drug use severity measures, and poten-
tial problems related to drug use.
Results
Participant characteristics
Overall participant sociodemographic characteristics
were reported in a previous article.14 Three-fourths of
the 686 participants were male. The average age was
36.9 years (SD= 13.2). The sample was ethnically diverse,
with a third being Latino. Sixty-five percent reported an
annual income of less than $10,000 per year. Cannabis
was by far the most common drug used (84%). Fifty-
seven percent of participants were cannabis-only users.
The most common noncannabis drugs of use among
other drug users were amphetamines (46.7%), cocaine
(21.5%), heroin (18.8%), and opiates (17.9%).
Differences among drug use groups
Table 1 presents comparisons among nondaily
cannabis-only users, daily cannabis-only users, and
other drug users. The three drug use groups did not dif-
fer with regard to gender, race/ethnicity, marital status,
education, employment status, and medical ASI scores.
Both groups of cannabis-only users were significantly
younger than other drug users, and nondaily cannabis-
only users had significantly higher income levels than
other drug users. Forty-five percent of the sample over-
all was identified as having problematic drug use
according to the DAST, a percentage that varied greatly
by drug use group (*19% for nondaily cannabis-only,
29% for daily cannabis-only, and 76% for other drug
users). Drug ASI severity scores varied significantly
by group, with nondaily cannabis-only users having
relatively low drug ASI scores, other drug users having
relatively high drug ASI scores, and daily cannabis-only
users being intermediate. Both groups of cannabis-only
users had lower psychiatric and alcohol ASI scores than
other drug users, yet did not differ significantly from
one another. All groups differed with regard to self-
efficacy for drug avoidance. Daily cannabis-only users
had the lowest self-efficacy, nondaily cannabis-only
users had the highest self-efficacy, and other drug
users were intermediate.
Discussion
Results suggest that ED patients who use drugs other
than cannabis are at particular risk for high drug use
severity and concomitant problems such as psychiatric
problems and alcohol use severity. However, 19–29%
of cannabis-only users were identified as having prob-
lematic drug use. Furthermore, daily cannabis-only
users fared less well than nondaily cannabis users
with regard to drug use severity indicators and self-
efficacy for avoiding drug use, even though they were
younger as a group.
Although cannabis may be less harmful to individual
health relative to other forms of drug use, heavier can-
nabis use is a concern because it may be associated with
mental and physical health problems.7–10,20 Cannabis
dependence does occur, and individuals often perceive
themselves as unable to stop.21 Daily cannabis-only
users in our study were found to have particularly
low confidence in avoiding drug use (compared with
nondaily cannabis users and even other drug users).
However, there is a distinction between self-efficacy
and motivation, perceived importance, and desire to
avoid drug use—daily cannabis users may not be moti-
vated or see the importance of avoiding use. Connor
et al.22 found low cannabis refusal self-efficacy was re-
lated to problematic use. Enhancement of motivation
Table 1. Comparison of Nondaily Cannabis-Only, Daily
Cannabis-Only, and Other Drug Users Visiting Two Large
Emergency Departments
Characteristic
Nondaily
cannabis
only
(n= 141)
Daily
cannabis
only
(n= 253)
Other
drug
users
(n = 292) p
Age, years mean (SD) 36.4 (13.3) 34.9 (12.2) 38.5 (13.3) 0.014a
Male, % 76.1 77.8 73.3 ns
Race/ethnicity, %
Hispanic/Latino 31.3 29.8 36.0
White non-Hispanic 38.9 30.5 38.8
Black 25.8 32.6 20.4
Other 4.0 7.1 4.8 ns
Marital status, %
Single 85.2 82.3 82.1
Married 14.8 17.7 17.9 ns
Education, years, mean (SD) 12.2 (2.1) 12.0 (2.4) 12.1 (2.2) ns
Income, category, mean (SD) 2.0 (1.5) 1.9 (1.4) 1.6 (1.2) 0.014b
Employed past 30 days, % 34.9 36.9 29.8 ns
Problematic drug
use based on DAST, %
18.8 28.8 75.7 0.000c
Drug ASI scores, mean (SD) 0.03 (0.03) 0.09 (0.04) 0.11 (0.10) 0.000c
Medical ASI scores,
mean (SD)
0.66 (0.20) 0.66 (0.19) 0.66 (0.20) ns
Psychiatric ASI
scores, mean (SD)
0.26 (0.23) 0.26 (0.22) 0.36 (0.25) 0.000a
Alcohol ASI scores,
mean (SD)
0.09 (0.14) 0.10 (0.14) 0.14 (0.19) 0.001a
Self efficacy, mean (SD) 3.8 (1.0) 2.6 (1.2) 3.1 (1.1) 0.000c
aNondaily and daily cannabis-only users significantly different from
other drug users.
bNondaily cannabis-only users significantly different from other drug
users.
cAll groups significantly different.
ASI, Addiction Severity Index; DAST, drug abuse screening test; ns, not
significant at the 0.05 level; SD, standard deviation.
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and self-efficacy beliefs could be an important target
of prevention and treatment. As with other drug
use, behavioral interventions and motivational en-
hancement appear to be useful with problematic can-
nabis use.21 Screening, brief intervention, and referral
to treatment (SBIRT) is a promising public health
strategy that has been implemented in EDs to reduce
risks associated with substance use.23–25 Although
SBIRT has been shown to be effective for alcohol mis-
use, its impact on drug use, including cannabis, is less
conclusive. However, SBIRT’s emphasis on motiva-
tion and harm reduction could fit well with cannabis
use reduction goals to the degree that many cannabis
users express interest in reducing use rather than
abstinence.21
Possible limitations of the study include not having
information about the reason for the ED visit and un-
certainty of the degree to which respondents are rep-
resentative of the overall ED population. Use of
cannabis in terms of medical or recreational use was
not analyzed, an important distinction since there is
some evidence that medical and recreational cannabis
users differ in their clinical characteristics.26 The
quantity used and the frequency of use per day were
not collected. In addition, reliance on self-reports
may have resulted in underestimates of cannabis use
and other drug use.
Across the drug use groups, 45% of the ED partici-
pants screened positive for problematic drug use, a per-
centage that varied considerably by type of drug
(cannabis vs. other) and frequency of use (daily vs. non-
daily). This information may assist emergency medicine
providers and social work professionals in matching
patients to appropriate intervention. For example, users
of drugs other than cannabis (and perhaps heavy, chronic
cannabis users) may need referral to specialty services for
further assessment. Recently, Konstantopoulos et al.5 sug-
gested a clinical decision rule for performing a detailed as-
sessment of ED patients for possible problematic drug use
that is based on the type of drug. Because the ED repre-
sents an important ‘‘opportunistic’’ venue for harm reduc-
tion and intervention efforts with drug users, hospital staff
and health educators screening for substance use should
be attentive to differences in use patterns among patients,
as some adverse consequences may depend on the type
and frequency of substances being used.
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